<DOC>
	<DOCNO>NCT01456169</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety fix dose combination azilsartan medoxomil plus chlorthalidone ( 40/12.5 40/25 mg ) , daily , participant grade 2 3 essential hypertension reach target blood pressure follow treatment 40 mg azilsartan medoxomil monotherapy 4 week .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Safety Fixed Dose Combination Azilsartan Medoxomil Chlorthalidone Patients With High Blood Pressure Who Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone</brief_title>
	<detailed_description>Eligible participant complete 2-week single-blind run-in period ( Days -42 -29 ) prior Single-Blind Monotherapy Treatment Period ( Day -28 Day -1 ) receive azilsartan medoxomil 40 mg. After Single-Blind Monotherapy Treatment Period , participant achieve target blood pressure discontinue treatment resume standard care management discretion treat physician , participant achieve target blood pressure ( define clinic systolic blood pressure ≥140 mmHg ) randomly assign 1 3 active treatment arm : azilsartan medoxomil 40 mg plus placebo , azilsartan medoxomil plus chlorthalidone 40/12.5 mg , azilsartan medoxomil plus chlorthalidone 40/25 mg .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<criteria>At Screening 1 . The participant grade 23 essential hypertension adequately control , define mean , trough , sit , clinic systolic blood pressure ( SBP ) : ≥160 ≤180 mm Hg participant receive antihypertensive medication 14 day prior Visit 1 . ≥150 ≤170 mm Hg participant take 1 antihypertensive medication Visit 1 . ≥140 ≤160 mm Hg participant take 2 antihypertensive medication Visit 1 . 2 . The participant clinical laboratory test result ( clinical chemistry , hematology , complete urinalysis ) within reference range test laboratory investigator consider result clinically relevant preclude entry study hypertensive population . 3 . The participant willing discontinue current antihypertensive medication . 4 . In opinion investigator , participant capable understand comply protocol requirement . 5 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 6 . Male female adult , least 18 year age . 7 . A female childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent 30 day last study drug dose . NOTE : Women NOT childbearing potential define surgically sterilize ( hysterectomy , bilateral oophorectomy , tubal ligation [ perform one 1 year prior Screening ] ) postmenopausal ( define least 1 year since last regular menses ) . Postplacebo runin : 8 . The participant must postplacebo runin , 24hour mean SBP ambulatory blood pressure monitoring ( ABPM ) 140175 mm Hg inclusive , clinic SBP measurement 160 190 mm Hg inclusive ( determine mean 3 sit , trough , measurement Day 29 ) qualify entry 4 week singleblind TAK491 40 mg monotherapy treatment period . Post4 week , singleblind TAK491 40 mg monotherapy treatment : 9 . The participant achieve target blood pressure ( define clinic SBP ≥140 mm Hg determine mean 3 sit , trough , measurement ) follow 4 week singleblind treatment TAK491 40 mg monotherapy Day 1 , prior randomization doubleblind treatment . At Screening 1 . The participant clinic diastolic blood pressure ( DBP ) &gt; 110 mm Hg . 2 . The participant 's 3 SBP measurement differ 15 mm Hg ( confirmed second set three measurement ) . 3 . The participant receive investigational compound within 30 day prior Screening currently participate another investigational study . NOTE : Participants participate observational study ( per local definition ) may enter Screening provide last intervention invasive procedure &gt; 30 day prior Visit 1 . 4 . The participant randomized/enrolled previous TAK491 TAK491CLD study . NOTE : This criterion apply participant enter screen placebo runin another TAK491 TAK491CLD study randomized/enrolled . 5 . The participant study site employee dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) may consent duress . 6 . The participant currently treat 2 antihypertensive medication . 7 . The participant work night ( third ) shift ( defined 11 PM [ 2300 ] 7 AM [ 0700 ] ) . 8 . The participant upper arm circumference &lt; 24 cm &gt; 42 cm . 9 . The participant secondary hypertension etiology ( e.g. , renovascular disease , pheochromocytoma , Cushing 's syndrome ) . 10 . The participant history myocardial infarction , heart failure , unstable angina , coronary artery bypass graft , percutaneous coronary intervention , hypertensive encephalopathy , cerebrovascular accident , persistent permanent atrial fibrillation transient ischemic attack . 11 . The participant clinically significant cardiac conduction defect ( e.g. , thirddegree atrioventricular block , sick sinus syndrome ) . 12 . The participant hemodynamically significant leave ventricular outflow obstruction due aortic valvular disease hypertrophic cardiomyopathy . 13 . The participant severe renal dysfunction disease [ base estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m^2 screen ] , prior renal transplantation nephrotic syndrome ( defined urinary albumin/creatinine ratio &gt; 2000 mg/g Screening ) . 14 . Participant know hemodynamically significant bilateral renal artery stenosis unilateral disease single kidney . 15 . The participant history cancer remission least 5 year prior first dose singleblind TAK491 monotherapy study drug . ( This criterion apply participant basal cell Stage 1 squamous cell carcinoma skin ) . 16 . The participant poorlycontrolled type 1 2 diabetes mellitus ( hemoglobin A1c [ HbA1c ] &gt; 8.5 % ) Screening . 17 . The participant hypokalemia hyperkalemia ( define serum potassium outside normal reference range central laboratory ) Screening . 18 . The participant alanine aminotransferase aspartate aminotransferase level &gt; 2.5 time upper limit normal , active liver disease , jaundice Screening . 19 . The participant know serious disease condition would compromise safety , might affect life expectancy , make difficult successfully manage follow participant accord protocol . 20 . The participant history hypersensitivity allergy angiotensin II receptor blocker ( ARB ) thiazidetype diuretic sulfonamidederived compound . 21 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse per local guideline within past 2 year . 22 . The participant require take excluded medication point study . 23 . If female , participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . Postplacebo runin period 24 . The participant clinic SBP &gt; 190 mm Hg DBP &gt; 115 mm Hg . 25 . The participant noncompliant ( &lt; 70 % &gt; 130 % ) study medication placebo runin period . 26 . The participant 24hour mean eligibility ABPM reading insufficient quality . Postsingleblind TAK491 40 mg treatment period 27 . The participant clinic SBP &gt; 180 mm Hg DBP &gt; 110 mm Hg . 28 . The participant noncompliant ( &lt; 70 % &gt; 130 % ) study medication TAK491 40 mg singleblind treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>High Blood Pressure</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>